BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026
Key Highlights
- ➤GLIX1 synergized with olaparib, veliparib, and niraparib across HR-proficient ovarian cancer lines
- ➤Low-dose GLIX1 plus olaparib significantly inhibited tumors versus vehicle in an HR-proficient PDX model
- ➤Combination activity exceeded each agent alone at respective optimal doses
- ➤GLIX1-olaparib tumor growth inhibition was comparable to cisplatin
- ➤BioLineRx plans an ovarian cancer arm in GLIX1’s Phase 1/2a expansion
Expert Statements
Philip Serlin, Chief Executive Officer of BioLineRx
“These preclinical findings extend the rationale for GLIX1 beyond glioblastoma, where we have already enrolled three dose-level patient cohorts in our Phase 1/2a clinical trial.”
Philip Serlin, Chief Executive Officer of BioLineRx
“Importantly, the in vivo results further strengthen the rationale for combining GLIX1 with PARP inhibitors, demonstrating meaningful anti-tumor activity in an HR-proficient ovarian cancer model even at reduced doses of both agents.”
Philip Serlin, Chief Executive Officer of BioLineRx
“We are very encouraged by these findings and look forward to further exploring GLIX1/PARP inhibitor combinations, including the planned addition of an ovarian cancer arm in the expansion phase of our ongoing clinical trial.”
Dr. Adam Robertson, Ph.D., Chief Scientific Officer of Hemispherian AS and presenting author of the abstract
“GLIX1 is designed to restore TET2 activity and drive tumor-selective DNA damage.”
Dr. Adam Robertson, Ph.D., Chief Scientific Officer of Hemispherian AS and presenting author of the abstract
“These findings suggest GLIX1 could remove the HR-deficiency requirement for PARPi activity, thereby both improving and broadening the use of PARP inhibitors in ovarian cancers, and we look forward to building on this work.”
BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026 PR Newswire
GLIX1 demonstrated reproducible synergy across different PARP inhibitors and multiple HR-proficient ovarian cancer cell lines, with high ZIP synergy scores, highlighting GLIX1's potential to expand the efficacy of PARP inhibitors
Get started
Create a free account to read the full story.